Exact Sciences (EXAS) Beats Q3 EPS by 6c, FY Revenue Guidance Tops Views

October 26, 2016 6:53 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Exact Sciences (NASDAQ: EXAS) reported Q3 EPS of ($0.36), $0.06 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $28.1 million versus the consensus estimate of $25.1 million.

  • reported completing 68,000 Cologuard tests vs consensus of 65,400 tests

GUIDANCE:

Exact Sciences sees FY2016 revenue of $93-95 million, versus the consensus of $90.9 million.

  • reiterated our FY 2016 guidance of completing approximately 240,000 Cologuard tests

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment